Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dermatofibroma Associated with Lymphoid Follicles Harboring Germinal Center: A Case Report.

Case reports in dermatology·2026
Same author

Hypopigmented Mycosis Fungoides With Childhood-Onset and Middle-Aged Onset: Two Case Reports Focusing on the Cutaneous Immune Microenvironment.

The Journal of dermatology·2026
Same author

Ichthyosiform pityriasis rubra pilaris-like eruption induced by ponatinib, successfully treated with topical vitamin D3 ointment.

European journal of dermatology : EJD·2026
Same author

Biomarker-based clustering identifies distinct pulmonary function trajectories in early systemic sclerosis.

Frontiers in immunology·2026
Same author

Clinical positioning and future prospects of JAK inhibitors in alopecia areata.

Expert opinion on pharmacotherapy·2026
Same author

Circumscribed Morphea Successfully Treated With Excimer Laser: Analysis of Histopathological Changes.

The Journal of dermatology·2026

Related Experiment Video

Updated: Jun 16, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Future treatments in systemic sclerosis.

Yoshihide Asano1

  • 1Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo 113-8655, Japan. yasano-tky@umin.ac.jp

The Journal of Dermatology
|February 24, 2010
PubMed
Summary
This summary is machine-generated.

Systemic sclerosis (SSc) treatments are emerging, targeting immune dysfunction and fibrosis. New therapies focus on transforming growth factor-beta (TGF-beta) signaling, immune modulation, and specific molecular pathways to combat SSc complications.

Related Experiment Videos

Last Updated: Jun 16, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Area of Science:

  • Immunology
  • Rheumatology
  • Fibrosis Research

Background:

  • Systemic sclerosis (SSc) is an autoimmune disease characterized by immune activation, fibrosis, and vascular damage.
  • Current SSc treatments are limited, necessitating the development of novel therapeutic strategies targeting underlying pathogenesis.

Purpose of the Study:

  • To review potential new therapeutic targets and emerging treatments for Systemic Sclerosis.
  • To explore strategies for inhibiting pathological TGF-beta signaling in SSc fibroblasts.
  • To identify novel targets for immune dysfunction and vascular complications in SSc.

Main Methods:

  • Review of current literature on SSc pathogenesis and therapeutic targets.
  • Analysis of potential strategies including TGF-beta pathway inhibition, immune modulation, and targeted therapies.
  • Examination of emerging treatments like imatinib mesylate for fibrosis and vasculopathy.

Main Results:

  • Transforming growth factor-beta (TGF-beta) pathway inhibitors (e.g., ALK5, Smad3 inhibitors) are key targets for fibrosis.
  • Connective tissue growth factor (CTGF)/CCN2, platelet-derived growth factor (PDGF), and endothelin-1 are identified as potential therapeutic targets.
  • Emerging therapies for immune dysfunction include i.v. immunoglobulin, stem cell transplantation, and B-cell depletion.
  • Targeted treatments for complications like Raynaud's phenomenon and pulmonary arterial hypertension involve phosphodiesterase-5 inhibitors and endothelin receptor antagonists.
  • Imatinib mesylate shows promise for SSc-related fibrosis and vasculopathy by modulating Fli1 expression.

Conclusions:

  • Multiple novel therapeutic strategies targeting TGF-beta signaling, immune pathways, and specific molecular targets are under development for SSc.
  • Targeted therapies offer potential for managing SSc complications such as fibrosis, vascular damage, and organ-specific manifestations.
  • Further research and clinical trials are essential to validate the efficacy and safety of these emerging SSc treatments.